Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Equity: 2022-2025

Historic Return on Equity for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -0.66%.

  • InMed Pharmaceuticals' Return on Equity rose 12.00% to -0.66% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.66%, marking a year-over-year increase of 12.00%. This contributed to the annual value of -0.72% for FY2025, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Return on Equity is -0.66%, which was up 17.77% from -0.80% recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Return on Equity ranged from a high of -0.51% in Q1 2024 and a low of -5.55% during Q3 2023.
  • Its 3-year average for Return on Equity is -1.56%, with a median of -0.80% in 2025.
  • Its Return on Equity has fluctuated over the past 5 years, first crashed by 364bps in 2023, then spiked by 477bps in 2024.
  • Over the past 4 years, InMed Pharmaceuticals' Return on Equity (Quarterly) stood at -1.34% in 2022, then crashed by 264bps to -3.97% in 2023, then soared by 289bps to -1.08% in 2024, then rose by 12bps to -0.66% in 2025.
  • Its Return on Equity stands at -0.66% for Q3 2025, versus -0.80% for Q2 2025 and -1.26% for Q1 2025.